Short Interest in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Declines By 30.4%

Ventyx Biosciences, Inc. (NASDAQ:VTYX) was the target of a large decline in short interest in January. As of January 15th, there was short interest totalling 6,680,000 shares, a decline of 30.4% from the December 31st total of 9,600,000 shares. Based on an average trading volume of 1,750,000 shares, the short-interest ratio is currently 3.8 days. Approximately 12.6% of the company’s stock are sold short.

Ventyx Biosciences Price Performance

NASDAQ VTYX opened at $2.05 on Friday. The stock has a 50-day simple moving average of $2.30 and a 200 day simple moving average of $2.26. Ventyx Biosciences has a twelve month low of $1.67 and a twelve month high of $11.48.

Wall Street Analysts Forecast Growth

VTYX has been the subject of a number of analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. HC Wainwright reaffirmed a “neutral” rating on shares of Ventyx Biosciences in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Insider Activity

In other Ventyx Biosciences news, CEO Raju Mohan purchased 238,248 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were bought at an average price of $1.83 per share, for a total transaction of $435,993.84. Following the purchase, the chief executive officer now directly owns 1,913,276 shares in the company, valued at $3,501,295.08. This trade represents a 14.22 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John Nuss sold 21,119 shares of Ventyx Biosciences stock in a transaction on Friday, December 27th. The shares were sold at an average price of $2.36, for a total transaction of $49,840.84. Following the completion of the sale, the insider now directly owns 464,582 shares of the company’s stock, valued at approximately $1,096,413.52. The trade was a 4.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have purchased a total of 630,000 shares of company stock worth $1,262,415 in the last ninety days. Corporate insiders own 18.18% of the company’s stock.

Institutional Investors Weigh In On Ventyx Biosciences

Several hedge funds have recently modified their holdings of VTYX. Palumbo Wealth Management LLC raised its stake in Ventyx Biosciences by 97.1% during the 4th quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company’s stock valued at $52,000 after purchasing an additional 11,792 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Ventyx Biosciences by 44.4% in the fourth quarter. Rhumbline Advisers now owns 132,825 shares of the company’s stock valued at $291,000 after buying an additional 40,813 shares during the period. Catalina Capital Group LLC acquired a new stake in Ventyx Biosciences during the fourth quarter worth about $25,000. JPMorgan Chase & Co. increased its stake in Ventyx Biosciences by 2.0% during the third quarter. JPMorgan Chase & Co. now owns 1,007,519 shares of the company’s stock valued at $2,196,000 after acquiring an additional 20,236 shares during the period. Finally, Barclays PLC raised its holdings in Ventyx Biosciences by 273.1% in the 3rd quarter. Barclays PLC now owns 80,295 shares of the company’s stock valued at $175,000 after acquiring an additional 58,776 shares in the last quarter. 97.88% of the stock is owned by institutional investors.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.